Department of Radiology and Neuroradiology, University Hospital of Cologne, Cologne, Germany.
Cerebrovasc Dis. 2012;34(1):70-7. doi: 10.1159/000338903. Epub 2012 Jun 30.
Stent retrievers are currently displacing 'classical' thrombectomy devices for recanalization in acute ischaemic stroke. The aim of our study was to show the procedural efficacy and safety of the Solitaire stent retriever as part of our multimodality endovascular approach in the treatment of ischaemic stroke.
Between March 2008 and December 2009, 104 patients [53 females (51%), 51 males (49%), mean age 67.3 years (range 31-96)] with 108 territorial occlusions were treated with the Solitaire stent alone or in conjunction with other endovascular stroke devices. All patients were referred to our service after clinical evaluation by a team of stroke neurologists as part of our standard treatment algorithm with 0.9 mg/kg i.v. recombinant tissue-type plasminogen activator and endovascular continuation of treatment in CT angiography-proven main branch occlusion. The time of angiography was defined as the moment of groin puncture. Final reperfusion success was rated according to the Thrombolysis in Cerebral Infarction (TICI) scale; the first persistent Thrombolysis in Myocardial Infarction (TIMI) 2/3 reperfusion was used for time-to-reperfusion measures.
Fifty-eight patients were treated in conjunction with intravenous lysis, 32/104 received intra-arterial lytics. Twenty-five territories were treated with the Solitaire alone; the remaining 83 were treated with a combination of mechanical thrombectomy devices or aspiration thrombectomy followed by or in conjunction with the Solitaire. The most frequent combination was a proximal aspiration/distal access catheter and Solitaire (62/108). In 15/108 procedures, temporary stenting without thrombectomy was performed. Eighty-three successful thrombectomy attempts were performed in the remaining 93 territories. The mean number of Solitaire passes was 2.46 (median 2, max. 12). The mean time from onset to reperfusion was 265 min (range 56-1,031), median 230 min; the mean angio-to-reperfusion time was 47 min (5-186), median 38.5 min. A subanalysis showed a significant reduction of the angio-to-reperfusion time when the Solitaire was used (48.7 vs. 68 min). The rate of final TICI 2b/3 reperfusion was 79% for the anterior and 77.9% for the posterior circulation (TIMI 2/3 for both: 92.5%). During or after the first deployment of the Solitaire, 72.8% showed TIMI 2/3 reperfusion. The mean National Institute of Health Stroke Scale score on admission was 15.3 and decreased by 7.8 points at clinical discharge. The overall mortality at discharge was 16% in the anterior and 47.8% in the posterior circulation group. There were 2 cases of periprocedural intracranial haemorrhage, unrelated to the Solitaire, 6 patients had evidence of subarachnoid haemorrhage, 2 potentially related to the Solitaire deployment. In 4/108 territories, thrombus migration to previously unaffected territories was noted. Vasospasm was seen in 13% of the target vessels. One device was inadvertently detached during retrieval. All these complications had no clinical consequence.
Our single-centre experience proves the technical feasibility and safety of the Solitaire for the treatment of acute intracranial vessel occlusion and approves previous reports with smaller patient numbers. Further multicentre studies with a randomized and prospective design will be necessary to verify the results.
支架取栓术目前已取代“经典”的血栓切除术,成为急性缺血性脑卒中再通的首选方法。本研究旨在展示 Solitaire 支架取栓术作为我们多模态血管内治疗缺血性脑卒中方案的一部分的程序疗效和安全性。
2008 年 3 月至 2009 年 12 月,104 例患者(53 例女性[51%],51 例男性[49%],平均年龄 67.3 岁[范围 31-96])因 108 个区域性闭塞接受了单纯 Solitaire 支架取栓或与其他血管内卒中治疗设备联合治疗。所有患者均在我们的服务中,经过卒中神经科医生团队的临床评估后,在接受 0.9mg/kg 静脉重组组织型纤溶酶原激活剂治疗后,根据 CT 血管造影证实的主要分支闭塞,继续进行血管内治疗。血管造影时间定义为腹股沟穿刺的时间。最终再灌注成功根据血栓溶栓(TICI)分级进行评定;首次持久的心肌梗死溶栓(TIMI)2/3 再灌注用于时间再灌注测量。
58 例患者联合静脉溶栓治疗,32/104 例患者接受了动脉内溶栓治疗。25 个靶区单独接受 Solitaire 治疗;其余 83 个靶区采用机械血栓切除术设备或抽吸血栓切除术联合 Solitaire 治疗。最常见的联合是近端抽吸/远端通路导管联合 Solitaire(62/108)。在 15/108 例手术中,进行了无血栓切除术的临时支架置入。在其余 93 个靶区中,成功进行了 83 次血栓切除术尝试。Solitaire 穿过的平均次数为 2.46 次(中位数 2 次,最大 12 次)。从发病到再灌注的平均时间为 265 分钟(范围 56-1031 分钟),中位数为 230 分钟;血管内到再灌注的平均时间为 47 分钟(5-186 分钟),中位数为 38.5 分钟。亚分析显示,当使用 Solitaire 时,血管内到再灌注时间显著缩短(48.7 分钟对 68 分钟)。前循环和后循环的最终 TICI 2b/3 再灌注率分别为 79%和 77.9%(两者的 TIMI 2/3 均为 92.5%)。在 Solitaire 首次放置过程中或之后,72.8%的患者显示 TIMI 2/3 再灌注。入院时平均国立卫生研究院卒中量表评分为 15.3 分,出院时下降 7.8 分。出院时总死亡率在前循环组为 16%,后循环组为 47.8%。有 2 例围手术期颅内出血与 Solitaire 无关,6 例患者有蛛网膜下腔出血的证据,2 例可能与 Solitaire 放置有关。在 4/108 个靶区中,发现血栓向先前未受影响的靶区迁移。在 13%的目标血管中出现血管痉挛。1 个设备在取回过程中不慎脱落。所有这些并发症均无临床后果。
我们的单中心经验证明了 Solitaire 治疗急性颅内血管闭塞的技术可行性和安全性,并证实了之前报道的较小患者数量的结果。进一步的多中心研究需要采用随机和前瞻性设计,以验证结果。